- Trials with a EudraCT protocol (135)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
135 result(s) found for: Aromatase Inhibitor.
Displaying page 1 of 7.
EudraCT Number: 2013-001064-27 | Sponsor Protocol Number: s55283 | Start Date*: 2013-06-25 |
Sponsor Name:University Hospitals Leuven | ||
Full Title: Placebo-controlled trial with vitamin D to prevent worsening/relieve aromatase inhibitor-induced musculoskeletal symptoms in breast cancer patients | ||
Medical condition: aromatase inhibitor-induced musculoskeletal symptoms in postmenopausal breast cancer patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: BE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2011-002157-64 | Sponsor Protocol Number: | Start Date*: 2012-03-07 |
Sponsor Name:Common Services Agency | ||
Full Title: ARomatase Inhibition plus minus SaracaTinib as Advanced breast CAncer Therapy: a randomised phase II study of aromatase inhibition plus/minus the src-inhibitor AZD0530 in post-menopausal women with... | ||
Medical condition: Advanced breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-001234-34 | Sponsor Protocol Number: 118 | Start Date*: 2020-04-08 | ||||||||||||||||
Sponsor Name:HUS Syöpäkeskus | ||||||||||||||||||
Full Title: Effects of Vaginal Estrogens on Serum Estradiol Levels in Postmenopausal Women with Breast Cancer Taking an Aromatase Inhibitor. | ||||||||||||||||||
Medical condition: Breast cancer, postmenopausal atrophic vaginitis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Elderly | Gender: Female | |||||||||||||||||
Trial protocol: FI (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001022-17 | Sponsor Protocol Number: 170304 | Start Date*: 2017-05-08 |
Sponsor Name:Breastcentre, Capio St Gorans Hospital | ||
Full Title: Vitamin D supplementation to breast cancer patients with adjuvant endocrine treatment – An observational clinical study where the patient is its own control. | ||
Medical condition: Breast cancer survivors on adjuvant treatment with an aromatase inhibitor having joint pain | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-005680-25 | Sponsor Protocol Number: C/22/2011 | Start Date*: 2012-04-24 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: A Phase II study to assess the safety and efficacy of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER positive locally advanced or metastatic breast cancer pati... | |||||||||||||
Medical condition: Locally advanced or metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004874-42 | Sponsor Protocol Number: TRAFO001 | Start Date*: 2009-02-06 | |||||||||||
Sponsor Name:Institut für Frauengesundheit GmbH | |||||||||||||
Full Title: Evaluation of predictive Factors for the Effectivity of Aromatase Inhibitor Therapy - Offene, prospektive, multizentrische Phase IV-Studie zur Untersuchung des Einflusses von pharmakogenetischen M... | |||||||||||||
Medical condition: The study examines the influence of pharmacogenetic markers on the efficacy and side effects in postmenopausal, steroid hormone positive breast cancer patients, who are treated with Letrozol. The p... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003185-25 | Sponsor Protocol Number: GO29058 | Start Date*: 2015-03-03 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE III, DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMIZED STUDY OF TASELISIB PLUS FULVESTRANT VERSUS PLACEBO PLUS FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE AND HER2 NEGATI... | |||||||||||||
Medical condition: WOMEN WITH ER-POSITIVE AND HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAS DIDEASE RECURRENCE OR PROGRESSION DURING OR AFTER AROMATASE INHIBITOR THERAPY | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Ongoing) PT (Completed) ES (Completed) CZ (Completed) DE (Completed) AT (Completed) NL (Completed) PL (Completed) BG (Completed) FR (Completed) SE (Completed) GR (Completed) RO (Ongoing) FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003104-11 | Sponsor Protocol Number: 1.0 | Start Date*: 2005-10-11 |
Sponsor Name:Fertility clinic Odense University Hospital | ||
Full Title: Androgen priming in the late luteal phase as a mean to improve the outcome of ovarian stimulation for IVF in normogonadotrophic women with a previously proven poor response | ||
Medical condition: Hypothesis. By combining pituitary downregulation with aromatase inhibitor, and hCG injection during a late luteal phase a powerful stimulation of thecal androgen production is achieved. Thereby, i... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: DK (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-002132-10 | Sponsor Protocol Number: MO27775 | Start Date*: 2012-03-08 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A randomized, two-arm, open-label, multicenter Phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first line patien... | |||||||||||||
Medical condition: HER2- and hormone receptor-positive advanced (metastatic or locally advanced) breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) ES (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002217-34 | Sponsor Protocol Number: FITO-01/21 | Start Date*: 2022-07-26 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI | |||||||||||||
Full Title: Tuscany project to investigate on efficacy and safety of Cannabis phytotherapic preparations for the treatment of Aromatase iNhibitor-induced chronic resistaNt pAin in Breast cancer patIents: a pro... | |||||||||||||
Medical condition: Aromatase iNhibitor-induced chronic resistaNt pAin in Breast cancer patIents | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005752-16 | Sponsor Protocol Number: CR0207-22 | Start Date*: 2008-03-03 | |||||||||||
Sponsor Name:Cancer Research UK | |||||||||||||
Full Title: A Cancer Research UK randomised phase II trial of ATN-224 (copper binding agent) in combination with exemestane versus exemestane alone in post-menopausal women with recurrent or advanced, oestroge... | |||||||||||||
Medical condition: recurrent or advanced oestrogen and/or progesterone receptor positive breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004517-84 | Sponsor Protocol Number: ITFE-2026-C10 | Start Date*: 2015-02-26 |
Sponsor Name:ITF Research Pharma S.L.U | ||
Full Title: A PHASE II PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND MULTI-CENTRE CLINICAL TRIAL TO ASSESS THE SAFETY OF 0.005 % ESTRIOL VAGINAL GEL IN HORMONE RECEPTOR-POSITIVE POSTMENOPAUSAL ... | ||
Medical condition: In postmenopausal hormone receptor positive breast cancer, treatment with aromatase inhibitors is the most effective and well-studied therapy. Lack of adherence is common due to the side-effects; v... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: ES (Completed) SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-000727-15 | Sponsor Protocol Number: 9238IL/0048 | Start Date*: 2004-12-03 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Randomized, Double Blind, Multicenter Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX™) vs. Exemestane (AROMASIN™) in Postmenopausal Women with Hormone Receptor Positive A... | ||
Medical condition: Hormone receptor positive breast cancer with disease progression after prior non-steroidal aromatase inhibitor (AI) therapy | ||
Disease: | ||
Population Age: Elderly | Gender: Female | |
Trial protocol: HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-000106-19 | Sponsor Protocol Number: GO29689 | Start Date*: 2015-12-10 | |||||||||||
Sponsor Name:Genentech, Inc | |||||||||||||
Full Title: A PHASE II, OPEN-LABEL, RANDOMIZED STUDY OF GDC-0810 VERSUS FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH ADVANCED OR METASTATIC ER+/HER2- BREAST CANCER RESISTANT TO AROMATASE INHIBITOR THERAPY | |||||||||||||
Medical condition: Advanced or Metastatic ER+/HER2- Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002623-41 | Sponsor Protocol Number: endo 220604 | Start Date*: 2004-09-10 |
Sponsor Name:Anders Nyboe Andersen, klinikchef, dr. med., Fertilitetsklinikken afsnit 4071, Rigshospitalet | ||
Full Title: Anvendelse af aromatase-inhibitor (Arimidex) i kombination med GnRH agonist (Zoladex) som forbehandling til IVF hos patienter med ovariel endometriose | ||
Medical condition: endometriosis ovarii | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: DK (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004433-93 | Sponsor Protocol Number: RIOTCSTUDY22017 | Start Date*: 2018-05-01 | ||||||||||||||||
Sponsor Name:Nicholas Stephen Macklon, Professor, MD, PhD | ||||||||||||||||||
Full Title: RIOT C: REDUCING THE IMPACT OF OVARIAN STIMULATION. NOVEL APPROACHES TO LUTEAL SUPPORT IN IVF. STUDY 2. | ||||||||||||||||||
Medical condition: Ovarian stimulation in oocyte donation | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-003510-13 | Sponsor Protocol Number: IRST174.08 | Start Date*: 2013-05-07 | |||||||||||
Sponsor Name:IRCCS ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI | |||||||||||||
Full Title: A phase II non randomized study evaluating the role of Androgen Receptors as Targets for therapy of pre-treated post-menopausal patients with ER/PgR-negative/AR-positive or ER and/or PgR-positive/A... | |||||||||||||
Medical condition: pre-treated post-menopausal patients with ER/PgR-negative/AR-positive or ER and/or PgR-positive/AR-positive metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002334-23 | Sponsor Protocol Number: 2017-03 | Start Date*: 2017-09-29 |
Sponsor Name:Dutch Breast Cancer Research Group (BOOG) | ||
Full Title: Selecting the Optimal position of CDK4/6 Inhibitors in HR+ Advanced breast cancer: the SONIA trial | ||
Medical condition: hormone receptor positive advanced breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-001208-23 | Sponsor Protocol Number: 2014/VCC/0013 | Start Date*: 2015-01-15 |
Sponsor Name:Velindre NHS Trust | ||
Full Title: A randomised, double blind, placebo controlled, phase II study of fulvestrant with or without the addition of vandetanib as treatment for patients with metastatic breast cancer resistant to aromata... | ||
Medical condition: Metastatic breast cancer that has become resistant to aromatase inhibitor therapy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002264-27 | Sponsor Protocol Number: ENGOT-ov54/Swiss-GO-2/MATAO | Start Date*: 2021-03-17 |
Sponsor Name:Swiss GO Trial Group | ||
Full Title: MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer: a randomized double-blinded placebo-controlled multi-center phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO) including LOGOS ... | ||
Medical condition: Patients with low and high grade serous and endometrioid ovarian cancer patients. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: AT (Ongoing) DE (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.